KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1102375, encodeId=862211023e5bb, content=我们做研究时最常见或撰写的SCI文章类型是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193918, encodeId=0c822193918a3, content=投稿半个月，这个状态Administratively Withdrawal是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6b25538707, createdName=123。, createdTime=Mon Mar 18 17:13:15 CST 2024, time=2024-03-18, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1102376, encodeId=46fa11023e6d1, content=如何判断SCI文章类型？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978172, encodeId=f0be9e81728c, content=友好好投的杂志因子也看涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/3d54f1aa13074fc6b9dc28ebe0abf990/04587b87b45e4b189cdfd64278e5d2b8.jpg, createdBy=76e51665341, createdName=democracy, createdTime=Wed Jun 30 11:41:06 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507799, encodeId=d16b50e79989, content=一审4个半月，大修，二审已经50天了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Fri Nov 21 16:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578461, encodeId=63575e8461fb, content=生理学和药理学领域的原创：化学物质与生物系统的作用机理，药理作用，利用和相互作用以及新药靶标的开发，计算模型进一步了解生理或药理过程的理论文章，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=878a2459333, createdName=123asd, createdTime=Fri Oct 25 09:36:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526652, encodeId=d39d5266527d, content=多久online？xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, beContent=xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=746f1926525, createdName=1e0bcf4bm96(暂无匿称), createdTime=Thu Sep 01 14:10:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508373, encodeId=dfbd5083e3ef, content=二审70天了，依然没有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Thu Dec 11 20:19:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505475, encodeId=c6585054e593, content=一审4个半月，两个审稿人，大修，问题很客观。二审自己认真准备很多资料和数据进行逐条回答，一个半月回小修后接受。二审审稿人A提了一个小问题，很容易。B对之前的解释很满意，直接接受。（对审稿人B的回答包括进一步实验的部分数据补充，虽然没有加入文章，但也OK) 感觉只要严谨客观，应该是没有问题，但是审稿确实很慢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Aug 21 10:38:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504939, encodeId=07495049394f, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：太慢了，4月2日投稿，到现在都没有消息，催了两次，编辑说都在审稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Sat Aug 02 11:50:00 CST 2014, time=2014-08-02, status=1, ipAttribution=)]

2021-12-29 MS68862005

我们做研究时最常见或撰写的SCI文章类型是什么？

57 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1102375, encodeId=862211023e5bb, content=我们做研究时最常见或撰写的SCI文章类型是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193918, encodeId=0c822193918a3, content=投稿半个月，这个状态Administratively Withdrawal是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6b25538707, createdName=123。, createdTime=Mon Mar 18 17:13:15 CST 2024, time=2024-03-18, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1102376, encodeId=46fa11023e6d1, content=如何判断SCI文章类型？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978172, encodeId=f0be9e81728c, content=友好好投的杂志因子也看涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/3d54f1aa13074fc6b9dc28ebe0abf990/04587b87b45e4b189cdfd64278e5d2b8.jpg, createdBy=76e51665341, createdName=democracy, createdTime=Wed Jun 30 11:41:06 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507799, encodeId=d16b50e79989, content=一审4个半月，大修，二审已经50天了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Fri Nov 21 16:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578461, encodeId=63575e8461fb, content=生理学和药理学领域的原创：化学物质与生物系统的作用机理，药理作用，利用和相互作用以及新药靶标的开发，计算模型进一步了解生理或药理过程的理论文章，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=878a2459333, createdName=123asd, createdTime=Fri Oct 25 09:36:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526652, encodeId=d39d5266527d, content=多久online？xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, beContent=xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=746f1926525, createdName=1e0bcf4bm96(暂无匿称), createdTime=Thu Sep 01 14:10:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508373, encodeId=dfbd5083e3ef, content=二审70天了，依然没有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Thu Dec 11 20:19:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505475, encodeId=c6585054e593, content=一审4个半月，两个审稿人，大修，问题很客观。二审自己认真准备很多资料和数据进行逐条回答，一个半月回小修后接受。二审审稿人A提了一个小问题，很容易。B对之前的解释很满意，直接接受。（对审稿人B的回答包括进一步实验的部分数据补充，虽然没有加入文章，但也OK) 感觉只要严谨客观，应该是没有问题，但是审稿确实很慢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Aug 21 10:38:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504939, encodeId=07495049394f, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：太慢了，4月2日投稿，到现在都没有消息，催了两次，编辑说都在审稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Sat Aug 02 11:50:00 CST 2014, time=2014-08-02, status=1, ipAttribution=)]

2024-03-18 123。来自山西省

投稿半个月，这个状态Administratively Withdrawal是拒稿了吗

62 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1102375, encodeId=862211023e5bb, content=我们做研究时最常见或撰写的SCI文章类型是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193918, encodeId=0c822193918a3, content=投稿半个月，这个状态Administratively Withdrawal是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6b25538707, createdName=123。, createdTime=Mon Mar 18 17:13:15 CST 2024, time=2024-03-18, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1102376, encodeId=46fa11023e6d1, content=如何判断SCI文章类型？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978172, encodeId=f0be9e81728c, content=友好好投的杂志因子也看涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/3d54f1aa13074fc6b9dc28ebe0abf990/04587b87b45e4b189cdfd64278e5d2b8.jpg, createdBy=76e51665341, createdName=democracy, createdTime=Wed Jun 30 11:41:06 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507799, encodeId=d16b50e79989, content=一审4个半月，大修，二审已经50天了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Fri Nov 21 16:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578461, encodeId=63575e8461fb, content=生理学和药理学领域的原创：化学物质与生物系统的作用机理，药理作用，利用和相互作用以及新药靶标的开发，计算模型进一步了解生理或药理过程的理论文章，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=878a2459333, createdName=123asd, createdTime=Fri Oct 25 09:36:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526652, encodeId=d39d5266527d, content=多久online？xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, beContent=xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=746f1926525, createdName=1e0bcf4bm96(暂无匿称), createdTime=Thu Sep 01 14:10:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508373, encodeId=dfbd5083e3ef, content=二审70天了，依然没有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Thu Dec 11 20:19:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505475, encodeId=c6585054e593, content=一审4个半月，两个审稿人，大修，问题很客观。二审自己认真准备很多资料和数据进行逐条回答，一个半月回小修后接受。二审审稿人A提了一个小问题，很容易。B对之前的解释很满意，直接接受。（对审稿人B的回答包括进一步实验的部分数据补充，虽然没有加入文章，但也OK) 感觉只要严谨客观，应该是没有问题，但是审稿确实很慢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Aug 21 10:38:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504939, encodeId=07495049394f, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：太慢了，4月2日投稿，到现在都没有消息，催了两次，编辑说都在审稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Sat Aug 02 11:50:00 CST 2014, time=2014-08-02, status=1, ipAttribution=)]

2021-12-27 MS54455111222

如何判断SCI文章类型？

67 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1102375, encodeId=862211023e5bb, content=我们做研究时最常见或撰写的SCI文章类型是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193918, encodeId=0c822193918a3, content=投稿半个月，这个状态Administratively Withdrawal是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6b25538707, createdName=123。, createdTime=Mon Mar 18 17:13:15 CST 2024, time=2024-03-18, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1102376, encodeId=46fa11023e6d1, content=如何判断SCI文章类型？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978172, encodeId=f0be9e81728c, content=友好好投的杂志因子也看涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/3d54f1aa13074fc6b9dc28ebe0abf990/04587b87b45e4b189cdfd64278e5d2b8.jpg, createdBy=76e51665341, createdName=democracy, createdTime=Wed Jun 30 11:41:06 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507799, encodeId=d16b50e79989, content=一审4个半月，大修，二审已经50天了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Fri Nov 21 16:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578461, encodeId=63575e8461fb, content=生理学和药理学领域的原创：化学物质与生物系统的作用机理，药理作用，利用和相互作用以及新药靶标的开发，计算模型进一步了解生理或药理过程的理论文章，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=878a2459333, createdName=123asd, createdTime=Fri Oct 25 09:36:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526652, encodeId=d39d5266527d, content=多久online？xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, beContent=xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=746f1926525, createdName=1e0bcf4bm96(暂无匿称), createdTime=Thu Sep 01 14:10:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508373, encodeId=dfbd5083e3ef, content=二审70天了，依然没有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Thu Dec 11 20:19:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505475, encodeId=c6585054e593, content=一审4个半月，两个审稿人，大修，问题很客观。二审自己认真准备很多资料和数据进行逐条回答，一个半月回小修后接受。二审审稿人A提了一个小问题，很容易。B对之前的解释很满意，直接接受。（对审稿人B的回答包括进一步实验的部分数据补充，虽然没有加入文章，但也OK) 感觉只要严谨客观，应该是没有问题，但是审稿确实很慢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Aug 21 10:38:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504939, encodeId=07495049394f, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：太慢了，4月2日投稿，到现在都没有消息，催了两次，编辑说都在审稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Sat Aug 02 11:50:00 CST 2014, time=2014-08-02, status=1, ipAttribution=)]

2021-06-30 democracy

友好好投的杂志因子也看涨

79 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1102375, encodeId=862211023e5bb, content=我们做研究时最常见或撰写的SCI文章类型是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193918, encodeId=0c822193918a3, content=投稿半个月，这个状态Administratively Withdrawal是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6b25538707, createdName=123。, createdTime=Mon Mar 18 17:13:15 CST 2024, time=2024-03-18, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1102376, encodeId=46fa11023e6d1, content=如何判断SCI文章类型？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978172, encodeId=f0be9e81728c, content=友好好投的杂志因子也看涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/3d54f1aa13074fc6b9dc28ebe0abf990/04587b87b45e4b189cdfd64278e5d2b8.jpg, createdBy=76e51665341, createdName=democracy, createdTime=Wed Jun 30 11:41:06 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507799, encodeId=d16b50e79989, content=一审4个半月，大修，二审已经50天了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Fri Nov 21 16:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578461, encodeId=63575e8461fb, content=生理学和药理学领域的原创：化学物质与生物系统的作用机理，药理作用，利用和相互作用以及新药靶标的开发，计算模型进一步了解生理或药理过程的理论文章，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=878a2459333, createdName=123asd, createdTime=Fri Oct 25 09:36:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526652, encodeId=d39d5266527d, content=多久online？xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, beContent=xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=746f1926525, createdName=1e0bcf4bm96(暂无匿称), createdTime=Thu Sep 01 14:10:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508373, encodeId=dfbd5083e3ef, content=二审70天了，依然没有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Thu Dec 11 20:19:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505475, encodeId=c6585054e593, content=一审4个半月，两个审稿人，大修，问题很客观。二审自己认真准备很多资料和数据进行逐条回答，一个半月回小修后接受。二审审稿人A提了一个小问题，很容易。B对之前的解释很满意，直接接受。（对审稿人B的回答包括进一步实验的部分数据补充，虽然没有加入文章，但也OK) 感觉只要严谨客观，应该是没有问题，但是审稿确实很慢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Aug 21 10:38:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504939, encodeId=07495049394f, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：太慢了，4月2日投稿，到现在都没有消息，催了两次，编辑说都在审稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Sat Aug 02 11:50:00 CST 2014, time=2014-08-02, status=1, ipAttribution=)]

2014-11-21 guyingzsu

一审4个半月，大修，二审已经50天了，还没有消息。

373 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1102375, encodeId=862211023e5bb, content=我们做研究时最常见或撰写的SCI文章类型是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193918, encodeId=0c822193918a3, content=投稿半个月，这个状态Administratively Withdrawal是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6b25538707, createdName=123。, createdTime=Mon Mar 18 17:13:15 CST 2024, time=2024-03-18, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1102376, encodeId=46fa11023e6d1, content=如何判断SCI文章类型？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978172, encodeId=f0be9e81728c, content=友好好投的杂志因子也看涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/3d54f1aa13074fc6b9dc28ebe0abf990/04587b87b45e4b189cdfd64278e5d2b8.jpg, createdBy=76e51665341, createdName=democracy, createdTime=Wed Jun 30 11:41:06 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507799, encodeId=d16b50e79989, content=一审4个半月，大修，二审已经50天了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Fri Nov 21 16:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578461, encodeId=63575e8461fb, content=生理学和药理学领域的原创：化学物质与生物系统的作用机理，药理作用，利用和相互作用以及新药靶标的开发，计算模型进一步了解生理或药理过程的理论文章，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=878a2459333, createdName=123asd, createdTime=Fri Oct 25 09:36:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526652, encodeId=d39d5266527d, content=多久online？xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, beContent=xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=746f1926525, createdName=1e0bcf4bm96(暂无匿称), createdTime=Thu Sep 01 14:10:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508373, encodeId=dfbd5083e3ef, content=二审70天了，依然没有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Thu Dec 11 20:19:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505475, encodeId=c6585054e593, content=一审4个半月，两个审稿人，大修，问题很客观。二审自己认真准备很多资料和数据进行逐条回答，一个半月回小修后接受。二审审稿人A提了一个小问题，很容易。B对之前的解释很满意，直接接受。（对审稿人B的回答包括进一步实验的部分数据补充，虽然没有加入文章，但也OK) 感觉只要严谨客观，应该是没有问题，但是审稿确实很慢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Aug 21 10:38:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504939, encodeId=07495049394f, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：太慢了，4月2日投稿，到现在都没有消息，催了两次，编辑说都在审稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Sat Aug 02 11:50:00 CST 2014, time=2014-08-02, status=1, ipAttribution=)]

2019-10-25 123asd

生理学和药理学领域的原创：化学物质与生物系统的作用机理，药理作用，利用和相互作用以及新药靶标的开发，计算模型进一步了解生理或药理过程的理论文章，

153 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1102375, encodeId=862211023e5bb, content=我们做研究时最常见或撰写的SCI文章类型是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193918, encodeId=0c822193918a3, content=投稿半个月，这个状态Administratively Withdrawal是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6b25538707, createdName=123。, createdTime=Mon Mar 18 17:13:15 CST 2024, time=2024-03-18, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1102376, encodeId=46fa11023e6d1, content=如何判断SCI文章类型？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978172, encodeId=f0be9e81728c, content=友好好投的杂志因子也看涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/3d54f1aa13074fc6b9dc28ebe0abf990/04587b87b45e4b189cdfd64278e5d2b8.jpg, createdBy=76e51665341, createdName=democracy, createdTime=Wed Jun 30 11:41:06 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507799, encodeId=d16b50e79989, content=一审4个半月，大修，二审已经50天了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Fri Nov 21 16:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578461, encodeId=63575e8461fb, content=生理学和药理学领域的原创：化学物质与生物系统的作用机理，药理作用，利用和相互作用以及新药靶标的开发，计算模型进一步了解生理或药理过程的理论文章，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=878a2459333, createdName=123asd, createdTime=Fri Oct 25 09:36:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526652, encodeId=d39d5266527d, content=多久online？xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, beContent=xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=746f1926525, createdName=1e0bcf4bm96(暂无匿称), createdTime=Thu Sep 01 14:10:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508373, encodeId=dfbd5083e3ef, content=二审70天了，依然没有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Thu Dec 11 20:19:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505475, encodeId=c6585054e593, content=一审4个半月，两个审稿人，大修，问题很客观。二审自己认真准备很多资料和数据进行逐条回答，一个半月回小修后接受。二审审稿人A提了一个小问题，很容易。B对之前的解释很满意，直接接受。（对审稿人B的回答包括进一步实验的部分数据补充，虽然没有加入文章，但也OK) 感觉只要严谨客观，应该是没有问题，但是审稿确实很慢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Aug 21 10:38:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504939, encodeId=07495049394f, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：太慢了，4月2日投稿，到现在都没有消息，催了两次，编辑说都在审稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Sat Aug 02 11:50:00 CST 2014, time=2014-08-02, status=1, ipAttribution=)]

2016-09-01 1e0bcf4bm96(暂无匿称)

多久online？xzwsh 2014-01-07 发表::
研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。

xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。

384 0

[GetPortalCommentsPageByObjectIdResponse(id=1102375, encodeId=862211023e5bb, content=我们做研究时最常见或撰写的SCI文章类型是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193918, encodeId=0c822193918a3, content=投稿半个月，这个状态Administratively Withdrawal是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6b25538707, createdName=123。, createdTime=Mon Mar 18 17:13:15 CST 2024, time=2024-03-18, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1102376, encodeId=46fa11023e6d1, content=如何判断SCI文章类型？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978172, encodeId=f0be9e81728c, content=友好好投的杂志因子也看涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/3d54f1aa13074fc6b9dc28ebe0abf990/04587b87b45e4b189cdfd64278e5d2b8.jpg, createdBy=76e51665341, createdName=democracy, createdTime=Wed Jun 30 11:41:06 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507799, encodeId=d16b50e79989, content=一审4个半月，大修，二审已经50天了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Fri Nov 21 16:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578461, encodeId=63575e8461fb, content=生理学和药理学领域的原创：化学物质与生物系统的作用机理，药理作用，利用和相互作用以及新药靶标的开发，计算模型进一步了解生理或药理过程的理论文章，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=878a2459333, createdName=123asd, createdTime=Fri Oct 25 09:36:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526652, encodeId=d39d5266527d, content=多久online？xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, beContent=xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=746f1926525, createdName=1e0bcf4bm96(暂无匿称), createdTime=Thu Sep 01 14:10:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508373, encodeId=dfbd5083e3ef, content=二审70天了，依然没有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Thu Dec 11 20:19:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505475, encodeId=c6585054e593, content=一审4个半月，两个审稿人，大修，问题很客观。二审自己认真准备很多资料和数据进行逐条回答，一个半月回小修后接受。二审审稿人A提了一个小问题，很容易。B对之前的解释很满意，直接接受。（对审稿人B的回答包括进一步实验的部分数据补充，虽然没有加入文章，但也OK) 感觉只要严谨客观，应该是没有问题，但是审稿确实很慢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Aug 21 10:38:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504939, encodeId=07495049394f, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：太慢了，4月2日投稿，到现在都没有消息，催了两次，编辑说都在审稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Sat Aug 02 11:50:00 CST 2014, time=2014-08-02, status=1, ipAttribution=)]

2014-12-11 guyingzsu

二审70天了，依然没有消息

337 0

[GetPortalCommentsPageByObjectIdResponse(id=1102375, encodeId=862211023e5bb, content=我们做研究时最常见或撰写的SCI文章类型是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193918, encodeId=0c822193918a3, content=投稿半个月，这个状态Administratively Withdrawal是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6b25538707, createdName=123。, createdTime=Mon Mar 18 17:13:15 CST 2024, time=2024-03-18, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1102376, encodeId=46fa11023e6d1, content=如何判断SCI文章类型？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978172, encodeId=f0be9e81728c, content=友好好投的杂志因子也看涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/3d54f1aa13074fc6b9dc28ebe0abf990/04587b87b45e4b189cdfd64278e5d2b8.jpg, createdBy=76e51665341, createdName=democracy, createdTime=Wed Jun 30 11:41:06 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507799, encodeId=d16b50e79989, content=一审4个半月，大修，二审已经50天了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Fri Nov 21 16:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578461, encodeId=63575e8461fb, content=生理学和药理学领域的原创：化学物质与生物系统的作用机理，药理作用，利用和相互作用以及新药靶标的开发，计算模型进一步了解生理或药理过程的理论文章，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=878a2459333, createdName=123asd, createdTime=Fri Oct 25 09:36:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526652, encodeId=d39d5266527d, content=多久online？xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, beContent=xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=746f1926525, createdName=1e0bcf4bm96(暂无匿称), createdTime=Thu Sep 01 14:10:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508373, encodeId=dfbd5083e3ef, content=二审70天了，依然没有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Thu Dec 11 20:19:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505475, encodeId=c6585054e593, content=一审4个半月，两个审稿人，大修，问题很客观。二审自己认真准备很多资料和数据进行逐条回答，一个半月回小修后接受。二审审稿人A提了一个小问题，很容易。B对之前的解释很满意，直接接受。（对审稿人B的回答包括进一步实验的部分数据补充，虽然没有加入文章，但也OK) 感觉只要严谨客观，应该是没有问题，但是审稿确实很慢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Aug 21 10:38:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504939, encodeId=07495049394f, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：太慢了，4月2日投稿，到现在都没有消息，催了两次，编辑说都在审稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Sat Aug 02 11:50:00 CST 2014, time=2014-08-02, status=1, ipAttribution=)]

2014-08-21 匿名用户

一审4个半月，两个审稿人，大修，问题很客观。二审自己认真准备很多资料和数据进行逐条回答，一个半月回小修后接受。二审审稿人A提了一个小问题，很容易。B对之前的解释很满意，直接接受。（对审稿人B的回答包括进一步实验的部分数据补充，虽然没有加入文章，但也OK) 感觉只要严谨客观，应该是没有问题，但是审稿确实很慢~

446 0

[GetPortalCommentsPageByObjectIdResponse(id=1102375, encodeId=862211023e5bb, content=我们做研究时最常见或撰写的SCI文章类型是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193918, encodeId=0c822193918a3, content=投稿半个月，这个状态Administratively Withdrawal是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6b25538707, createdName=123。, createdTime=Mon Mar 18 17:13:15 CST 2024, time=2024-03-18, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1102376, encodeId=46fa11023e6d1, content=如何判断SCI文章类型？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978172, encodeId=f0be9e81728c, content=友好好投的杂志因子也看涨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/3d54f1aa13074fc6b9dc28ebe0abf990/04587b87b45e4b189cdfd64278e5d2b8.jpg, createdBy=76e51665341, createdName=democracy, createdTime=Wed Jun 30 11:41:06 CST 2021, time=2021-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=507799, encodeId=d16b50e79989, content=一审4个半月，大修，二审已经50天了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=373, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Fri Nov 21 16:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578461, encodeId=63575e8461fb, content=生理学和药理学领域的原创：化学物质与生物系统的作用机理，药理作用，利用和相互作用以及新药靶标的开发，计算模型进一步了解生理或药理过程的理论文章，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=878a2459333, createdName=123asd, createdTime=Fri Oct 25 09:36:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=526652, encodeId=d39d5266527d, content=多久online？xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, beContent=xzwsh 2014-01-07 发表:: 研究方向：药理学;心肌缺血再灌注; 接收率：约75% 审稿时间：约1个月 11月14投稿，12月11号修回，提的问题不是很尖锐，不难回答，12月21号回稿，一月六号接收，没有再提任何修改意见。对于质量不是太高的文章，投这个杂志还是不错的，还免费。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=384, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=746f1926525, createdName=1e0bcf4bm96(暂无匿称), createdTime=Thu Sep 01 14:10:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508373, encodeId=dfbd5083e3ef, content=二审70天了，依然没有消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=337, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Thu Dec 11 20:19:00 CST 2014, time=2014-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=505475, encodeId=c6585054e593, content=一审4个半月，两个审稿人，大修，问题很客观。二审自己认真准备很多资料和数据进行逐条回答，一个半月回小修后接受。二审审稿人A提了一个小问题，很容易。B对之前的解释很满意，直接接受。（对审稿人B的回答包括进一步实验的部分数据补充，虽然没有加入文章，但也OK) 感觉只要严谨客观，应该是没有问题，但是审稿确实很慢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=446, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Thu Aug 21 10:38:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=504939, encodeId=07495049394f, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：太慢了，4月2日投稿，到现在都没有消息，催了两次，编辑说都在审稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=411, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b2bf104129, createdName=guyingzsu, createdTime=Sat Aug 02 11:50:00 CST 2014, time=2014-08-02, status=1, ipAttribution=)]

2014-08-02 guyingzsu

审稿速度:6.0 | 投稿命中率:50.0
经验分享：太慢了，4月2日投稿，到现在都没有消息，催了两次，编辑说都在审稿。

411 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务